De-escalation

June 7, 2020

Now Enrolling: The CompassHER2 pCR trial is determining if certain patients with early-stage HER2 positive breast cancer may benefit from reduced chemotherapy

The purpose of this study is to find out if some patients with early-stage HER2 positive breast cancer can safely be treated with less chemotherapy than is generally used.
June 8, 2020

Now Enrolling: The DECREASE trial seeks to decrease treatment side effects – and improve quality of life – for people with early-stage anal cancer

This study is evaluating whether lower doses of chemoradiation will be able to effectively treat early-stage anal squamous cell carcinoma while also decreasing side effects.
June 9, 2020
Pills on scale

Cancer treatment de-escalation: improving cancer care by tailoring treatment

De-escalation is an effort to reduce the intensity of treatment without sacrificing efficacy. This issue covers several de-escalation trials: DECREASE, CompassHER2 pCR, and E3311.